Medication leaflets

Active substance

Results for the substance atovaquone proguanil

4 results

About this active substance

Atovaquone+proguanil is a combination medication used for the prevention and treatment of malaria, an infectious disease caused by Plasmodium parasites. Atovaquone works by inhibiting electron transport in the parasite's mitochondria, while proguanil is a dihydrofolate reductase inhibitor, interfering with the parasite's DNA synthesis.

This combination is administered orally, usually once daily, and is indicated for both malaria prophylaxis in travelers and the treatment of acute uncomplicated malaria. It is effective against multiple Plasmodium species, including P. falciparum, which is resistant to other antimalarial drugs.

Common side effects include nausea, vomiting, abdominal pain, and headache. In rare cases, severe adverse reactions such as allergic reactions or liver function impairment may occur. It is important for patients to adhere to the recommended dosing schedule to prevent the development of parasite resistance.

Atovaquone+proguanil is a safe and effective option for the prevention and treatment of malaria, contributing to the global effort to reduce the burden of this infectious disease.